DNAJC5 and malaria: The Pf-CSP antigen is the primary component of the RTS,S [2], which is one of the leading malaria vaccine candidates, and the only one to have shown moderate, but promising, results during Phase II trials in adults in The Gambia [3] and children in Mozambique [4].